A new review pooling the available literature on legume-derived biopeptides confirms their ‘tremendous potential’ for type 2 diabetes (T2D) treatment, but this is thwarted by issues of stability and bioavailability
Fava bean peptides isolated by artificial intelligence performed better than traditional milk protein to improve muscle conditioning, according to a study supported by Irish biotechnology company Nuritas.
With a couple of ingredients already on the market for muscle and cellular aging, Nuritas’ next wave of artificial intelligence driven ingredient discoveries will target some big consumer health needs, including glucose management and very specialized...
Health tech startup Nuritas has built an extensive peptide knowledge base using its proprietary AI and genomics platform Nπϕ (Nuritas Peptide Finder). The platform analyzes billions of untapped peptides in plants and natural food sources to predict and...
Nuritas has raised €40m ($45m) in the Irish biotech firm’s latest round of funding intended to finance global expansion efforts and potential new additions to its portfolio of plant-based bioactive peptides.
With its first purchase order from Nestlé-owned Garden of Life in hand, Norwegian biotech company Hofseth BioCare (HBC) is gearing up for significant growth in North America with new products, exciting science, and unique claims.
Gelatine trade associations from four continents have formed a new global organisation that aims to boost consumer awareness of gelatine’s role in nutraceuticals, joint health and cosmetic applications.
Rousselot, the collagen-based ingredients producer, has revealed a new study which it says provides important answers surrounding the bioavailability of collagen peptides and the modifications they undergo during digestion.